Knight Therapeutics Inc (TSE:GUD) had its price objective upped by TD Securities from C$10.00 to C$11.00 in a report issued on Friday morning, reports. TD Securities currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. CIBC lifted their target price on shares of Knight Therapeutics from C$9.50 to C$9.80 in a research note on Friday, November 11th. Scotiabank reduced their price objective on shares of Knight Therapeutics from C$10.00 to C$9.50 and set an outperform rating for the company in a research note on Friday, November 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Knight Therapeutics currently has a consensus rating of Buy and an average target price of C$9.83.

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Knight Therapeutics (TSE:GUD) opened at 9.78 on Friday. Knight Therapeutics has a 1-year low of $5.89 and a 1-year high of $9.86. The company has a 50-day moving average price of $9.20 and a 200-day moving average price of $8.65. The firm has a market capitalization of $1.30 billion and a P/E ratio of 68.87.

About Knight Therapeutics

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Stock Target Prices

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.